Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment

scientific article

Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment is …
instance of (P31):
scholarly articleQ13442814

External links are
P819ADS bibcode2015PLoSO..1019483B
P356DOI10.1371/JOURNAL.PONE.0119483
P932PMC publication ID4351071
P698PubMed publication ID25741704
P5875ResearchGate publication ID273148631

P50authorRaymond J SteptoeQ59556035
Tony J. KennaQ37371728
P2093author name stringHideo Yagita
Alan L H Ching
Justin Large
Ryan Galea
Stephen J P Blake
P2860cites workCentral memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cellsQ24530100
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanomaQ24548019
Safety, activity, and immune correlates of anti-PD-1 antibody in cancerQ24633070
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) miceQ24670319
Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?Q27002575
The blockade of immune checkpoints in cancer immunotherapyQ27860852
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerQ27860857
The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans.Q50940546
Cognate CD4+ help elicited by resting dendritic cells does not impair the induction of peripheral tolerance in CD8+ T cells.Q53573163
PD-L1 is induced in hepatocytes by viral infection and by interferon-α and -γ and mediates T cell apoptosisQ57083098
Steady-state dendritic cells expressing cognate antigen terminate memory CD8+ T-cell responsesQ57667259
CD4+ T Cells Pass Through an Effector Phase During the Process of In Vivo Tolerance InductionQ61140374
Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysisQ79209903
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infectionQ36737159
Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockadeQ36927966
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cellsQ36986702
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.Q37524200
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical applicationQ38163290
Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cellsQ39122553
Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunityQ39549328
Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation.Q39763756
Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance.Q40647086
A combination of local inflammation and central memory T cells potentiates immunotherapy in the skinQ42403489
Targeting antigen to diverse APCs inactivates memory CD8+ T cells without eliciting tissue-destructive effector functionQ44234403
Transient gain of effector function by CD8+ T cells undergoing peripheral tolerance to high-dose self-antigenQ44631970
Premature terminal exhaustion of Friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors.Q45377151
Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional toleranceQ47755230
Improved Survival with Ipilimumab in Patients with Metastatic MelanomaQ27861062
PD-1 and its ligands in tolerance and immunityQ28131650
Two subsets of memory T lymphocytes with distinct homing potentials and effector functionsQ28146072
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cellsQ28243975
Adoptive immunotherapy for cancer: harnessing the T cell responseQ28262548
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytesQ28282689
Restoring function in exhausted CD8 T cells during chronic viral infectionQ28289222
T cell receptor antagonist peptides induce positive selectionQ29618820
Immunosuppressive networks in the tumour environment and their therapeutic relevanceQ29619244
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsQ29619686
Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanomaQ34034408
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell toleranceQ34122678
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunityQ34161493
Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.Q34193534
Tumor antigen cross-presentation and the dendritic cell: where it all begins?Q34210664
Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274).Q34484749
Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4.Q34554699
Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activationQ34570144
Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergyQ34575119
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cellsQ34578170
A potential new pathway for PD-L1 costimulation of the CD8-T cell response to Listeria monocytogenes infectionQ34586991
Dendritic cell programming by cytomegalovirus stunts naive T cell responses via the PD-L1/PD-1 pathway.Q34589567
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responsesQ34650346
Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.Q34801069
In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells.Q34827147
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.Q34891171
The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivoQ35140721
The roles of tumor-derived exosomes in cancer pathogenesisQ35606520
Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infectionQ36024206
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokinesQ36334073
Migratory properties of naive, effector, and memory CD8(+) T cellsQ36369485
Phenotypic and functional analysis of CD8(+) T cells undergoing peripheral deletion in response to cross-presentation of self-antigen.Q36376340
Immediate cytotoxicity but not degranulation distinguishes effector and memory subsets of CD8+ T cellsQ36399420
Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell toleranceQ36544963
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue3
P407language of work or nameEnglishQ1860
P921main subjectimmunotherapyQ1427096
P304page(s)e0119483
P577publication date2015-03-05
P1433published inPLOS OneQ564954
P1476titleBlockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment
P478volume10

Reverse relations

cites work (P2860)
Q47737204Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development
Q40152307Antigen presenting cell-targeted proinsulin expression converts insulin-specific CD8+ T-cell priming to tolerance in autoimmune-prone NOD mice
Q28066199Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
Q60935183Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors
Q38401589Development of novel avenues to overcome challenges facing CAR T cells
Q37655345Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation
Q92335228Immunotherapy using anti-PD-1 and anti-PD-L1 in Leishmania amazonensis-infected BALB/c mice reduce parasite load
Q27003955Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?
Q99579442Liposomal gp100 vaccine combined with CpG ODN sensitizes established B16F10 melanoma tumors to anti PD-1 therapy
Q36928580Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy
Q46047154New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone
Q98466646Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
Q90049764Single segment of spleen autotransplantation, after splenectomy for trauma, can restore splenic functions
Q59349036TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade
Q47252754The Role of Tumor Microenvironment in Cancer Immunotherapy.

Search more.